-DOCSTART- -X- O
The -X- _ O
living -X- _ O
epidermis -X- _ O
and -X- _ O
dermis -X- _ O
are -X- _ O
rich -X- _ O
in -X- _ O
antigen -X- _ O
presenting -X- _ O
cells -X- _ O
( -X- _ O
APCs -X- _ O
) -X- _ O
. -X- _ O
Their -X- _ O
activation -X- _ O
can -X- _ O
elicit -X- _ O
a -X- _ O
strong -X- _ O
humoral -X- _ O
and -X- _ O
cellular -X- _ O
immune -X- _ O
response -X- _ O
as -X- _ O
well -X- _ O
as -X- _ O
mucosal -X- _ O
immunity. -X- _ O
Therefore -X- _ O
, -X- _ O
the -X- _ O
skin -X- _ O
is -X- _ O
a -X- _ O
very -X- _ O
attractive -X- _ O
site -X- _ O
for -X- _ O
vaccination -X- _ O
, -X- _ O
and -X- _ O
an -X- _ O
intradermal -X- _ O
application -X- _ O
of -X- _ O
antigen -X- _ O
may -X- _ O
be -X- _ O
much -X- _ O
more -X- _ O
effective -X- _ O
than -X- _ O
a -X- _ O
subcutaneous -X- _ O
or -X- _ O
intramuscular -X- _ O
injection. -X- _ O
However -X- _ O
, -X- _ O
the -X- _ O
stratum -X- _ O
corneum -X- _ O
( -X- _ O
SC -X- _ O
) -X- _ O
is -X- _ O
a -X- _ O
most -X- _ O
effective -X- _ O
barrier -X- _ O
against -X- _ O
the -X- _ O
invasion -X- _ O
of -X- _ O
topically -X- _ O
applied -X- _ O
vaccines. -X- _ O
Products -X- _ O
which -X- _ O
have -X- _ O
reached -X- _ O
the -X- _ O
stage -X- _ O
of -X- _ O
clinical -X- _ O
testing -X- _ O
, -X- _ O
avoid -X- _ O
this -X- _ O
problem -X- _ O
by -X- _ O
injecting -X- _ B-Intervention
the -X- _ I-Intervention
nano‐vaccine -X- _ I-Intervention
intradermally -X- _ I-Intervention
or -X- _ O
by -X- _ O
employing -X- _ O
a -X- _ O
barrier -X- _ O
disrupting -X- _ O
method -X- _ O
and -X- _ O
applying -X- _ O
the -X- _ O
vaccine -X- _ O
to -X- _ O
a -X- _ O
relatively -X- _ O
large -X- _ O
skin -X- _ O
area. -X- _ O
Needle‐free -X- _ O
vaccination -X- _ O
is -X- _ O
desirable -X- _ O
from -X- _ O
a -X- _ O
number -X- _ O
of -X- _ O
aspects -X- _ O
: -X- _ O
ease -X- _ O
of -X- _ O
application -X- _ O
, -X- _ O
improved -X- _ O
patient -X- _ O
acceptance -X- _ O
and -X- _ O
less -X- _ O
risk -X- _ O
of -X- _ O
infection -X- _ O
among -X- _ O
them. -X- _ O
Nanocarriers -X- _ B-Intervention
can -X- _ O
be -X- _ O
designed -X- _ O
in -X- _ O
a -X- _ O
way -X- _ O
that -X- _ O
they -X- _ O
can -X- _ O
overcome -X- _ O
the -X- _ O
SC. -X- _ O
Also -X- _ O
incorporation -X- _ O
into -X- _ O
nanocarriers -X- _ O
protects -X- _ B-Outcome
instable -X- _ I-Outcome
antigen -X- _ I-Outcome
from -X- _ I-Outcome
degradation -X- _ I-Outcome
, -X- _ I-Outcome
improves -X- _ I-Outcome
uptake -X- _ I-Outcome
and -X- _ I-Outcome
processing -X- _ I-Outcome
by -X- _ I-Outcome
APCs -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
facilitates -X- _ I-Outcome
endosomal -X- _ I-Outcome
escape -X- _ I-Outcome
and -X- _ I-Outcome
nuclear -X- _ I-Outcome
delivery -X- _ I-Outcome
of -X- _ I-Outcome
DNA -X- _ I-Outcome
vaccines. -X- _ I-Outcome
In -X- _ O
addition -X- _ O
, -X- _ O
sustained -X- _ B-Outcome
release -X- _ I-Outcome
systems -X- _ I-Outcome
may -X- _ I-Outcome
build -X- _ I-Outcome
a -X- _ I-Outcome
depot -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
tissue -X- _ I-Outcome
gradually -X- _ I-Outcome
releasing -X- _ I-Outcome
antigen -X- _ I-Outcome
which -X- _ I-Outcome
may -X- _ I-Outcome
avoid -X- _ I-Outcome
booster -X- _ I-Outcome
doses. -X- _ I-Outcome
Therefore -X- _ O
, -X- _ O
nanoformulations -X- _ B-Intervention
of -X- _ I-Intervention
vaccines -X- _ I-Intervention
for -X- _ O
transcutaneous -X- _ O
immunization -X- _ O
are -X- _ O
currently -X- _ O
a -X- _ O
very -X- _ O
dynamic -X- _ O
field -X- _ O
of -X- _ O
research. -X- _ O
Among -X- _ O
the -X- _ O
huge -X- _ O
variety -X- _ O
of -X- _ O
nanocarrier -X- _ O
systems -X- _ O
that -X- _ O
are -X- _ O
investigated -X- _ O
hopes -X- _ O
lie -X- _ O
on -X- _ O
ultra‐flexible -X- _ O
liposomes -X- _ O
, -X- _ O
superfine -X- _ O
rigid -X- _ O
nanoparticles -X- _ O
and -X- _ O
nanocarriers -X- _ O
, -X- _ O
which -X- _ O
are -X- _ O
taken -X- _ O
up -X- _ O
by -X- _ O
hair -X- _ O
follicles. -X- _ O
The -X- _ O
potential -X- _ O
and -X- _ O
pitfalls -X- _ O
associated -X- _ O
with -X- _ O
these -X- _ O
three -X- _ O
classes -X- _ O
of -X- _ O
carriers -X- _ O
will -X- _ O
be -X- _ O
discussed -X- _ O
. -X- _ O

